This study investigates pancreatic adenocarcinoma. It involves the use of an investigational medication delivered directly to the tumor to determine the highest safe dose.
The study evaluates the safety of this investigational medication to ensure it does not cause unacceptable levels of side effects.
- Who can participate: Adults aged 18 and older with pancreatic adenocarcinoma that has not spread beyond the pancreas and regional lymph nodes can participate. Participants must have normal heart and lung function, be able to undergo specific medical procedures, and use birth control if they have partners of childbearing potential.
- Study details: Participants will receive a direct injection of the investigational medication into the tumor. The study focuses on finding the safest dose without procedural implications.